JAK2 and myeloproliferative disorder: TP53 mutations are among the most frequent genetic alterations in lung cancer and are linked to genomic instability and aggressive tumor behavior (1, 2).The JAK2 p.V617F mutation is a gain-of-function alteration well recognized in myeloproliferative neoplasms (MPNs) but rarely detected in solid tumors.